Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Sunday, January 19, 2025

Overcoming limitations of traditional CVD drugs

 A long time ago, our non-existent stroke leadership completely fucking failed at putting together magnetic nanoparticles delivering smaller loads of tPA resulting in much less chance of bleeds! Solving doctor reluctance.

We should have been using magnetic nanoparticles to deliver tPA for years.

6 months ago, your competent? doctor started working on nanozymes, right?  Oh, that's right, you DON'T have a functioning stroke doctor, do you?


The latest here:

Overcoming limitations of traditional CVD drugs

Cardiovascular diseases (CVDs) pose a significant threat to human health due to the high mortality and morbidity rates. Traditional drugs often have limited efficacy due to inherent constraints, such as low bioavailability and notable side effects.

As a highly regarded therapeutic strategy, nanotechnology offers new perspectives and means for treating CVDs. Nanozyme-based targeted therapeutic drugs specifically address the biological processes in areas affected by CVDs, thereby achieving precise treatment. Compared to traditional drugs, targeted nanozymes offer advantages, such as high efficiency, specificity, controllability, and fewer side effects, showing great efficacy in treating CVDs.

This paper explores the design strategies and mechanisms of nanozyme-based targeted therapy and introduces its application in key CVDs, such as ischemic stroke, myocardial infarction, and coronary heart disease. The challenges of introducing targeted nanozymes into clinical applications and the future development prospects in the treatment of CVDs are also discussed.

Source:
Journal reference:

Liu, L. et. al. (2025) Targeted nanozyme-enabled treatment of cardiovascular diseases. Acta Materia Medicadoi.org/10.15212/AMM-2024-0046

No comments:

Post a Comment